Allied Corp banner
A

Allied Corp
OTC:ALID

Watchlist Manager
Allied Corp
OTC:ALID
Watchlist
Price: 0.0005 USD Market Closed
Market Cap: $115.5

Relative Value

ALID doesn't have a meaningful market cap.

There is not enough data to reliably calculate the relative value of ALID.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

ALID Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Multiples Across Competitors

ALID Competitors Multiples
Allied Corp Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
CA
Allied Corp
OTC:ALID
115.5 USD 0 -0 -2.5 -2.4
US
Eli Lilly and Co
NYSE:LLY
982.7B USD 15.1 47.6 32.1 34.1
US
Johnson & Johnson
NYSE:JNJ
586.1B USD 6.2 21.9 15.2 18.7
CH
Roche Holding AG
SIX:ROG
294.5B CHF 4.8 31.2 13.2 15.3
UK
AstraZeneca PLC
LSE:AZN
243B GBP 5.6 32.4 17.8 25.1
CH
Novartis AG
SIX:NOVN
247.9B CHF 5.6 22.7 14 18
US
Merck & Co Inc
NYSE:MRK
302.6B USD 4.7 16.6 10.3 12.1
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK 4.4 13.4 9.8 11.4
IE
Endo International PLC
LSE:0Y5F
218B USD 94 -74.6 333.1 835.4
US
Pfizer Inc
NYSE:PFE
156.1B USD 2.5 20.1 7.5 10
UK
GSK plc
XETRA:GS71
105.8B EUR 2.8 16.1 8.1 11.5
P/E Multiple
Earnings Growth PEG
CA
A
Allied Corp
OTC:ALID
Average P/E: 24.7
Negative Multiple: -0
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
47.6
28%
1.7
US
Johnson & Johnson
NYSE:JNJ
21.9
7%
3.1
CH
Roche Holding AG
SIX:ROG
31.2
29%
1.1
UK
AstraZeneca PLC
LSE:AZN
32.4
26%
1.2
CH
Novartis AG
SIX:NOVN
22.7
15%
1.5
US
Merck & Co Inc
NYSE:MRK
16.6
14%
1.2
DK
Novo Nordisk A/S
CSE:NOVO B
13.4
7%
1.9
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -74.6 N/A N/A
US
Pfizer Inc
NYSE:PFE
20.1
26%
0.8
UK
GSK plc
XETRA:GS71
16.1
18%
0.9
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CA
A
Allied Corp
OTC:ALID
Average EV/EBITDA: 46.1
Negative Multiple: -2.5
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
32.1
18%
1.8
US
Johnson & Johnson
NYSE:JNJ
15.2
2%
7.6
CH
Roche Holding AG
SIX:ROG
13.2
5%
2.6
UK
AstraZeneca PLC
LSE:AZN
17.8
11%
1.6
CH
Novartis AG
SIX:NOVN
14
9%
1.6
US
Merck & Co Inc
NYSE:MRK
10.3
7%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
9.8
7%
1.4
IE
E
Endo International PLC
LSE:0Y5F
333.1
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.5
-4%
N/A
UK
GSK plc
XETRA:GS71
8.1
2%
4.1
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
CA
A
Allied Corp
OTC:ALID
Average EV/EBIT: 99.2
Negative Multiple: -2.4
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
34.1
17%
2
US
Johnson & Johnson
NYSE:JNJ
18.7
6%
3.1
CH
Roche Holding AG
SIX:ROG
15.3
6%
2.6
UK
AstraZeneca PLC
LSE:AZN
25.1
24%
1
CH
Novartis AG
SIX:NOVN
18
12%
1.5
US
Merck & Co Inc
NYSE:MRK
12.1
6%
2
DK
Novo Nordisk A/S
CSE:NOVO B
11.4
8%
1.4
IE
E
Endo International PLC
LSE:0Y5F
835.4
N/A N/A
US
Pfizer Inc
NYSE:PFE
10
-1%
N/A
UK
GSK plc
XETRA:GS71
11.5
12%
1